Hillsdale Investment Management Inc. decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 10.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 184,600 shares of the specialty pharmaceutical company’s stock after selling 22,000 shares during the period. Hillsdale Investment Management Inc. owned about 0.57% of Collegium Pharmaceutical worth $6,105,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in COLL. Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 59.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after purchasing an additional 538,337 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in shares of Collegium Pharmaceutical by 65.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares during the period. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Collegium Pharmaceutical by 161.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 511,698 shares of the specialty pharmaceutical company’s stock worth $23,692,000 after buying an additional 316,109 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in shares of Collegium Pharmaceutical by 897.2% in the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after acquiring an additional 242,310 shares during the period.
Analyst Upgrades and Downgrades
A number of research firms recently commented on COLL. Needham & Company LLC reiterated a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Weiss Ratings restated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Two analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical currently has a consensus rating of “Buy” and an average target price of $57.50.
Collegium Pharmaceutical Stock Performance
Shares of COLL opened at $35.02 on Wednesday. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The business has a 50-day simple moving average of $34.71 and a two-hundred day simple moving average of $38.54. The stock has a market cap of $1.14 billion, a price-to-earnings ratio of 17.17 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 52 week low of $29.19 and a 52 week high of $50.79.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The business’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the previous year, the firm earned $1.49 EPS. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Read More
- Five stocks we like better than Collegium Pharmaceutical
- Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet
- 3 Overlooked Energy ETFs Delivering Strong Returns and Income
- 3 Space Stocks That Could Outshine SpaceX After Its IPO
- JPMorgan’s Q2 Strength Gives the Stock Rally New Support
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report).
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
